Lee M. Krug
About
Lee M. Krug is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Lee M. Krug has authored 178 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Pulmonary and Respiratory Medicine, 94 papers in Oncology and 52 papers in Molecular Biology. Recurrent topics in Lee M. Krug's work include Occupational and environmental lung diseases (58 papers), Lung Cancer Research Studies (52 papers) and Lung Cancer Treatments and Mutations (51 papers). Lee M. Krug is often cited by papers focused on Occupational and environmental lung diseases (58 papers), Lung Cancer Research Studies (52 papers) and Lung Cancer Treatments and Mutations (51 papers). Lee M. Krug collaborates with scholars based in United States, Canada and United Kingdom. Lee M. Krug's co-authors include Mark G. Kris, Valerie W. Rusch, Vincent A. Miller, Christopher G. Azzoli, Naiyer A. Rizvi, Raja M. Flores, Kenneth E. Rosenzweig, Robert T. Heelan, Marjorie G. Zauderer and Ennapadam Venkatraman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Lee M. Krug
175 papers receiving 7.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lee M. Krug United States | 51 | 4.6k | 3.2k | 2.5k | 985 | 685 | 178 | 7.7k | ||
| Wilfried Eberhardt Germany | 39 | 5.3k 1.1× | 4.2k 1.3× | 1.7k 0.7× | 895 0.9× | 429 0.6× | 239 | 7.6k | ||
| Melissa L. Johnson United States | 42 | 3.4k 0.7× | 5.0k 1.5× | 2.3k 0.9× | 550 0.6× | 470 0.7× | 359 | 7.1k | ||
| Fred R. Hirsch United States | 45 | 4.2k 0.9× | 4.5k 1.4× | 3.3k 1.3× | 532 0.5× | 521 0.8× | 136 | 8.2k | ||
| Masahiko Higashiyama Japan | 45 | 3.6k 0.8× | 2.1k 0.7× | 1.5k 0.6× | 948 1.0× | 400 0.6× | 202 | 6.2k | ||
| Emiliano Calvo Spain | 45 | 2.7k 0.6× | 6.0k 1.9× | 3.1k 1.2× | 578 0.6× | 875 1.3× | 340 | 9.3k | ||
| Joo-Hang Kim South Korea | 42 | 6.7k 1.5× | 8.3k 2.6× | 3.1k 1.2× | 454 0.5× | 813 1.2× | 150 | 11.7k | ||
| Jamie E. Chaft United States | 43 | 6.4k 1.4× | 7.0k 2.2× | 1.9k 0.8× | 799 0.8× | 437 0.6× | 175 | 10.2k | ||
| Thomas E. Stinchcombe United States | 41 | 3.7k 0.8× | 3.9k 1.2× | 1.7k 0.7× | 660 0.7× | 312 0.5× | 215 | 6.9k | ||
| Antonio Jimeno United States | 36 | 1.4k 0.3× | 3.1k 0.9× | 2.3k 0.9× | 475 0.5× | 297 0.4× | 128 | 5.2k | ||
| Michael Smylie Canada | 30 | 4.4k 0.9× | 7.2k 2.2× | 2.4k 1.0× | 484 0.5× | 555 0.8× | 92 | 9.1k |
Countries citing papers authored by Lee M. Krug
Since
Specialization
Citations
This map shows the geographic impact of Lee M. Krug's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee M. Krug with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee M. Krug more than expected).
Fields of papers citing papers by Lee M. Krug
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lee M. Krug. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee M. Krug. The network helps show where Lee M. Krug may publish in the future.
Co-authorship network of co-authors of Lee M. Krug
This figure shows the co-authorship network connecting the top 25 collaborators of Lee M. Krug. A scholar is included among the top collaborators of Lee M. Krug based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee M. Krug. Lee M. Krug is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fennell, Dean A., et al.. (2024). P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma. Journal of Thoracic Oncology. 19(10). S281–S281.
2.
Naidoo, Jarushka, Catherine J. Murphy, Michael B. Atkins, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Journal for ImmunoTherapy of Cancer. 11(3). e006398–e006398.
3.
Zauderer, Marjorie G., Anne S. Tsao, Tao Dao, et al.. (2017). A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research. 23(24). 7483–7489.
4.
Paz‐Ares, Luis, Bradley W. Lash, István Albert, et al.. (2017). An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. ii48–ii49.
5.
Dolly, Saoirse, Andrew J. Wagner, Johanna C. Bendell, et al.. (2016). Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(12). 2874–2884.
6.
Wee, Marvin, et al.. (2016). Factors affecting preparers' and auditors' judgements about materiality and conciseness in integrated reporting. Other publications TiSEM.
7.
Lok, Benjamin H., M. Catherine Pietanza, Charles M. Rudin, et al.. (2015). The Factors Influencing the Utilization of Prophylactic Cranial Irradiation in Patients With Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 93(3). E420–E421.
8.
Billè, Andrea, Lee M. Krug, Kaitlin M. Woo, Valerie W. Rusch, & Marjorie G. Zauderer. (2015). Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 11(2). 249–255.
9.
Varghese, Anna M., Maureen F. Zakowski, Helena A. Yu, et al.. (2014). Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. Journal of Thoracic Oncology. 9(6). 892–896.
10.
Pietanza, M. Catherine, Kyuichi Kadota, Kety Huberman, et al.. (2012). Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Clinical Cancer Research. 18(4). 1138–1145.
11.
Pietanza, M. Catherine, Shirish M. Gadgeel, Afshin Dowlati, et al.. (2012). Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(5). 856–865.
12.
Paik, Paul K., Charles M. Rudin, M. Catherine Pietanza, et al.. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 74(3). 481–485.
13.
Dubey, Sarita, Pasi A. Jänne, Lee M. Krug, et al.. (2010). A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology. 5(10). 1655–1661.
14.
James, Leonard P., Christopher G. Azzoli, Lee M. Krug, et al.. (2007). Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6.
15.
Rizvi, Naiyer A., Mark G. Kris, Vincent A. Miller, et al.. (2007). A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations. Molecular Cancer Therapeutics. 6.
16.
Azzoli, Christopher G., Lee M. Krug, Vincent A. Miller, et al.. (2007). A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(7). 638–644.
17.
James, Leonard P., Valerie W. Rusch, Binsheng Zhao, et al.. (2007). P3-097: Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non–squamous NSCLC. Journal of Thoracic Oncology. 2(8). S720–S720.
18.
López‐Ríos, Fernando, Shannon Chuai, Raja M. Flores, et al.. (2006). Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Research. 66(6). 2970–2979.
19.
Zhao, Binsheng, Lawrence H. Schwartz, Raja M. Flores, et al.. (2005). Automated segmentation of mesothelioma volume on CT scan. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 5747. 866–866.
20.
Azzoli, Christopher G., Lee M. Krug, Vincent A. Miller, Mark G. Kris, & R. Mass. (2002). Trastuzumab in the treatment of non–small cell lung cancer. Seminars in Oncology. 29(1). 59–65.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Melissa L. Johnson Breakdown of academic impact, for papers by Fred R. Hirsch Breakdown of academic impact, for papers by Masahiko Higashiyama Breakdown of academic impact, for papers by Emiliano Calvo Breakdown of academic impact, for papers by Joo-Hang Kim Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Thomas E. Stinchcombe Breakdown of academic impact, for papers by Antonio Jimeno Breakdown of academic impact, for papers by Michael Smylie